Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2021.04.034
Abstract: OBJECTIVE We reviewed our institutional data to evaluate toxicity and efficacy outcomes of pembrolizumab/lenvatinib in recurrent endometrial cancer in a "real-world" clinical setting and to compare the impact of reduced lenvatinib starting dose on outcomes.… read more here.
Keywords: recurrent endometrial; recommended reduced; toxicity; endometrial cancer ... See more keywords